1. Clinical & Scientific Overview
Piroxicam & Meloxicam (TIP-MED-000116, Reference Code [7.14]) is classified under
Pain, Inflammation, Rheumatology & Gout Medicines (Ch 07) as a Long-Half-Life Oxicam NSAIDs — Non-Selective & Preferential COX-2 Inhibitors (Schedule H).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 07 [7.14], p. 85): Piroxicam: Dolonex DT (Pfizer), Pirox (Cipla), Suganril. Meloxicam: Muvera (Sun), Mobic, Mel-OD (Zydus) — Strengths & Dosage Forms: Piroxicam Dispersible/Oral Tablets: 20 mg; Gel: 0.5%; IM: 20 mg/mL. Meloxicam Tablets: 7.5 mg, 15 mg
Piroxicam Dispersible/Oral Tablets: 20 mg; Gel: 0.5%; IM: 20 mg/mL. Meloxicam Tablets: 7.5 mg, 15 mg
3. Mechanism of Action & Pharmacodynamics
Long-Half-Life Oxicam NSAIDs — Non-Selective & Preferential COX-2 Inhibitors (Schedule H) acting on target receptor/enzyme pathways in Pain, Inflammation, Rheumatology & Gout Medicines (Ch 07): clinical efficacy is mediated via Long-Half-Life Oxicam NSAIDs — Non-Selective & Preferential COX-2 Inhibitors (Schedule H) for Osteoarthritis, rheumatoid arthritis, ankylosing spondylitis (Piroxicam has an extremely long half-life of ~50 hours and the highest GI bleeding/perforation risk among oral NSAIDs — restrict to second-line short-term specialist use!).
4. Therapeutic Indications & Evidence-Supported Uses
- Osteoarthritis, rheumatoid arthritis, ankylosing spondylitis (Piroxicam has an extremely long half-life of ~50 hours and the highest GI bleeding/perforation risk among oral NSAIDs — restrict to second-line short-term specialist use!)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Piroxicam: 20 mg PO OD (Max 20 mg/day). Meloxicam: 7.5 mg PO OD, max 15 mg OD
Administration & Meal Timing: Take immediately AFTER a full meal with a glass of water; co-prescribe a PPI if GI risk factors exist | Once Daily after Breakfast or Lunch
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Avoid if eGFR <45 mL/min; strictly contraindicated if eGFR <30 mL/min. Hepatic: Contraindicated in severe hepatic failure
Renal: Avoid if eGFR <45 mL/min; strictly contraindicated if eGFR <30 mL/min. Hepatic: Contraindicated in severe hepatic failure
Renal: Avoid if eGFR <45 mL/min; strictly contraindicated if eGFR <30 mL/min. Hepatic: Contraindicated in severe hepatic failure
7. Contraindications, Precautions & High-Risk Warnings
- CONTRAINDICATED in active/history of peptic ulcer or GI bleeding, CKD Stage 3b–5 (eGFR <45 mL/min), Heart Failure, IHD/stroke, 3rd trimester of pregnancy, AERD, and post-CABG
Key Clinical Precautions: Renal: Avoid if eGFR <45 mL/min; strictly contraindicated if eGFR <30 mL/min. Hepatic: Contraindicated in severe hepatic failure
8. Adverse Effects Profile
- Dyspepsia, epigastric pain, nausea, ankle oedema, blood pressure elevation
- Upper GI ulceration, perforation, or life-threatening haemorrhage, acute kidney injury, SJS/TEN, myocardial infarction/stroke
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- NEVER combine with another NSAID, systemic Steroids, or Anticoagulants/Antiplatelets (Apixaban, Rivaroxaban, Warfarin, Clopidogrel, Aspirin — massive GI bleed risk as seen in Case 15
- 2!); Triple Whammy AKI with ACEi/ARB + Diuretic; increases Lithium and Methotrexate toxicity
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Never take Dolonex DT or Muvera on an empty stomach or combine with any other painkiller; stop immediately and go to emergency if black tarry stools or coffee-ground vomiting occur
- Meal & Clock Timing Instruction: Take immediately AFTER a full meal with a glass of water; co-prescribe a PPI if GI risk factors exist (Once Daily after Breakfast or Lunch)
- Missed Dose Protocol: Use PRN or skip if missed; never exceed 20 mg/d of Piroxicam or 15 mg/d of Meloxicam
- Geriatric Dispensing Pearl: Piroxicam is strongly contraindicated in older adults (AGS Beers 2023 & STOPP v3) due to its 50-hour half-life and high rate of fatal GI bleeding and AKI
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Piroxicam Dispersible/Oral Tablets: 20 mg; Gel: 0.5%; IM: 20 mg/mL. Meloxicam Tablets: 7.5 mg, 15 mg
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 07 [7.14] (p. 85)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [7.16] Mefenamic Acid — Anthranilic Acid (Fenamate) COX-1 / COX-2 Inhibitor & Prostagland
- [7.17] Celecoxib — Selective Cyclooxygenase-2 (COX-2) Inhibitor — Diaryl-Substituted
- [7.18] Indomethacin — Potent Indole Acetic Acid Non-Selective COX Inhibitor (Schedule H
- [7.19] Tapentadol Hydrochloride — Centrally Acting Dual Mu-Opioid Receptor Agonist & Norepinephrine
